🇹🇷 Turkey Country × Condition
multiple sclerosis Clinical Trials in Turkey
Active clinical trials for multiple sclerosis with research sites in Turkey. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 5 // Recruiting: 5 // Updated: Daily
Total Trials
5
Recruiting Now
5
Country
🇹🇷 Turkey
Active Trials in Turkey (5)
NCT07137624
Recruiting
Motor Imagery and Action Observation for Gait Function in MS
Enrollment
20 pts
Country
🇹🇷 Turkey
Hacettepe University
View Trial → NCT07116070
Recruiting
Sarcopenia and Related Factors in Patients With Multiple Sclerosis
Enrollment
90 pts
Country
🇹🇷 Turkey
Selcuk University
View Trial → NCT07489794
Recruiting
URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS
Enrollment
47 pts
Country
🇹🇷 Turkey
Prof. Dr. Cemil Tascıoglu Education...
View Trial → NCT06511154
Recruiting
The Effect of Cognitive Exercise on Upper Extremity Functions, Balance and Cognitive Functions in Multiple Sclerosis
Enrollment
32 pts
Country
🇹🇷 Turkey
Ankara Yildirim Beyazıt University
View Trial → NCT07466823
Recruiting
Classification of Upper and Lower Limb Spasticity Patterns and Their Impact on Quality of Life in Patients With Multiple Sclerosis
Enrollment
75 pts
Country
🇹🇷 Turkey
Marmara University
View Trial → Frequently Asked Questions
How many multiple sclerosis clinical trials are active in Turkey?
There are currently 5 active clinical trials for multiple sclerosis with sites in Turkey, of which 5 are actively recruiting patients.
How can I join a multiple sclerosis clinical trial in Turkey?
To join a multiple sclerosis clinical trial in Turkey, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Turkey directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are multiple sclerosis trials in Turkey?
Active multiple sclerosis trials in Turkey span multiple phases. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.